Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jason Huo
Observed names:
J. Huo,
Jianghua Huo
Observed institution:
Intra Cellular Therapies (United States)
ORCID:
0009-0004-2748-951X
Observed ORCID:
0009-0004-2748-951X
OpenAlex ID:
A5109603537
The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses
2023
·
Roger S. McIntyre
, Suresh Durgam
, et al.
·
European Neuropsychopharmacology
·
48
Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial
2025
·
Suresh Durgam
, Susan G. Kozauer
, et al.
·
Journal of Clinical Psychopharmacology
·
23
The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features
2023
·
Roger S. McIntyre
, Suresh Durgam
, et al.
·
The Journal of Clinical Psychiatry
·
22
PDF
M205. Long-term Safety of Lumateperone (iti-007): Metabolic Effects in a 1-year Study
2020
·
Andrew Satlin
, Suresh Durgam
, et al.
·
Schizophrenia Bulletin
·
4
Metabolic Syndrome in Bipolar Depression with Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials
2023
·
Christoph U Correll
, Susan G Kozauer
, et al.
·
CNS Spectrums
·
3
PDF
Lumateperone in the treatment of major depressive disorder and bipolar depression with mixed features: efficacy across symptoms
2024
·
S. Durgam
, S.G. Kozauer
, et al.
·
Neuroscience Applied
·
1
S221. the Efficacy of Lumateperone 42 Mg in the Treatment of Schizophrenia Symptoms Associated With Social Functioning: Post Hoc Analysis of an Acute Placebo- and Active-controlled Trial
2020
·
Kimberly Vanover
, Robert Davis
, et al.
·
Schizophrenia Bulletin
·
1
Independent and Joint Associations of Socioeconomic Status and Dietary Quality with Depressive and Anxiety Symptoms Among Chinese Older Adults: A Cross-Sectional Study of the Chinese Longitudinal Healthy Longevity Survey
2026
·
Jianghua Huo
, Chongyu Ding
, et al.
·
Nutrients
Reply to Letter From Surekha et al: “Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions”
2025
·
Suresh Durgam
, Susan G. Kozauer
, et al.
·
Journal of Clinical Psychopharmacology
Lumateperone Treatment for Major Depressive Episodes With Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar Ii Disorder
2025
·
*Zubin Bhagwagar
, Susan G Kozauer
, et al.
·
The International Journal of Neuropsychopharmacology
Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder With Anxious Distress and Mixed Features
2025
·
*Zubin Bhagwagar
, Susan G Kozauer
, et al.
·
The International Journal of Neuropsychopharmacology
Lumateperone in the treatment of patients with major depressive disorder and bipolar disorder with anxious distress and mixed features
2024
·
W. Earley
, S.G. Kozauer
, et al.
·
Neuroscience Applied
Lumateperone treatment for major depressive episodes with mixed features in major depressive disorder and bipolar I or bipolar II disorder
2023
·
S. Durgam
, S.G. Kozauer
, et al.
·
Neuroscience Applied
lumateperone (ITI-007) in the treatment of bipolar depression: efficacy across symptoms
2022
·
R.S. McIntyre
, J. Edwards
, et al.
·
Neuroscience Applied
PDF
P.0420 The efficacy of lumateperone in patients with bipolar depression with and without mixed features
2021
·
R. McIntyre
, S. Durgam
, et al.
·
European Neuropsychopharmacology
P.446 Efficacy and safety of lumateperone (ITI-007) in the treatment of depressive episodes associated with bipolar I and II disorders
2020
·
S. Durgam
, A. Satlin
, et al.
·
European Neuropsychopharmacology
Show more works
View as search
Works count:
16
Citation count:
102
H-index:
4
I10-index:
3
Year
Topic
Type
